Effects of clopidogrel therapy on whole blood platelet aggregation, the Plateletworks® assay and coagulation parameters in cats with asymptomatic hypertrophic cardiomyopathy: a pilot study
| Autor: | den Toom, M L, van Leeuwen, M W, Szatmári, V, Teske, E, Sub Cardiologie, Universitair Veterinair Diagnostisch Lab, Sub Oncologie/Cytologie, dCSCA AVR |
|---|---|
| Přispěvatelé: | Sub Cardiologie, Universitair Veterinair Diagnostisch Lab, Sub Oncologie/Cytologie, dCSCA AVR |
| Rok vydání: | 2016 |
| Předmět: |
Male
Platelet Aggregation Pilot Projects 030204 cardiovascular system & hematology Cat Diseases Fibrinogen arterial 0403 veterinary science 0302 clinical medicine Platelet Prospective Studies Whole blood platelet lcsh:Veterinary medicine Hypertrophic cardiomyopathy Cat 04 agricultural and veterinary sciences Clopidogrel clopidogrel platelet Adenosine Diphosphate ardiomyopathy Cardiology Platelet aggregation inhibitor Female medicine.symptom circulatory and respiratory physiology medicine.drug medicine.medical_specialty Ticlopidine 040301 veterinary sciences Asymptomatic Feline 03 medical and health sciences Double-Blind Method Internal medicine medicine Animals cardiovascular diseases arterial thromboembolism Blood Coagulation clopidogrel General Veterinary business.industry Cardiomyopathy Hypertrophic thromboembolism medicine.disease Asymptomatic Diseases Cats lcsh:SF600-1100 business cardiomyopathy Platelet Aggregation Inhibitors |
| Zdroj: | Veterinary Quarterly, 37(1), 8. Koninklijke Nederlandse Maatschappij voor Diergeneeskunde Veterinary Quarterly, Vol 37, Iss 1, Pp 8-15 (2017) |
| ISSN: | 1875-5941 0165-2176 |
| DOI: | 10.1080/01652176.2016.1244618 |
| Popis: | BACKGROUND: Although scientific evidence is limited, clopidogrel is frequently used as prophylaxis for arterial thromboembolism in cats with hypertrophic cardiomyopathy (HCM). OBJECTIVES: Evaluating effects of clopidogrel therapy in asymptomatic cats with HCM on (1) conventional whole blood aggregation (WBA), (2) alternative platelet aggregation assessed with tubes of the Plateletworks® assay and (3) standard coagulation parameters. ANIMALS AND METHODS: Prospective, randomized, double-blind, placebo-controlled pilot study. Fourteen asymptomatic HCM cats were randomly allocated to receive placebo (n = 5) or clopidogrel (18.75 mg/cat q24h, n = 9) as part of a larger study. Aggregation responses (to 20 µM adenosine diphosphate (ADP) and 10 µg/ml collagen) in WBA and the Plateletworks® assay and standard coagulation parameters were evaluated at baseline and after seven days of therapy. RESULTS: Clopidogrel therapy significantly reduced aggregation responses to ADP and collagen in the Plateletworks® agonists tubes (ADP and collagen: P < 0.001), but did not significantly reduce aggregation responses to ADP and collagen in the WBA technique (ADP: P = 0.07, collagen: P = 0.30). Clopidogrel therapy did not show a significant effect on prothrombin time, activated partial thromboplastin time, antithrombin, D-dimers and fibrinogen concentrations. CONCLUSION AND CLINICAL IMPORTANCE: Clopidogrel therapy at a dose of 18.75 mg/cat q24h for seven days causes a significant decrease in in vitro platelet aggregation evaluated with the Plateletworks® assay, without affecting standard coagulation parameters in cats with asymptomatic HCM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|